• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

aptarpharma

Aptar reports positive adherence results with iPump dose software

April 14, 2025 By Sean Whooley

Aptar Digital health iPump (1) (1)

Aptar Digital Health today announced survey findings showcasing the impact of its iPump connected assistant for medication adherence. The SPEED survey looked at iPump’s effect on adherence to Stallergenes Greer’s sublingual liquid immunotherapy (SLIT). Stallergenes Greer will present findings at the CFA congress (Congrès Francophone d’Allergologie) in Paris this week. iPump, developed in conjunction with […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Patient Monitoring, Pharmaceuticals, Technology Tagged With: aptarpharma

Nasal vaccine devices: Design and regulatory need-to-knows

February 14, 2025 By Jim Hammerand

A photo of a nasal vaccine device spraying mist.

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses. In 2024, the FDA approved a nasal spray as the first at-home influenza vaccination, allowing adults to vaccinate themselves or someone in their care without a needle jab or a trip to the pharmacy. Intranasal vaccines […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: aptarpharma

Aptar Pharma inks dev deal with Pulmotree for non-propellant liquid inhaler platform

September 13, 2024 By Sean Whooley

Aptar Pharma Pulmontree Aptar Pharma Pulmontree Kolibri inhaler

Aptar Pharma announced that it entered into an exclusive collaboration agreement with Pulmotree to develop a liquid inhaler platform. The collaboration enables Aptar to lead the development and promotion of the Kolibri non-propellant liquid inhaler (NPLI) platform. Under the agreement, Aptar intends to provide Pulmotree with full support to accelerate growth. The company serves as […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Technology Tagged With: aptarpharma, Pulmotree

Aptar Group’s Unidose system to deliver neffy nasal epinephrine

August 16, 2024 By Sean Whooley

ARS Pharmaceuticals neffy nasal epinephrine

Aptar announced today that its Unidose liquid system received FDA approval to deliver ARS Pharmaceuticals’ neffy (epinephrine nasal spray). ARS won FDA approval last week for neffy as an emergency treatment for patients with Type I allergic reactions, including anaphylaxis. It marked a major innovation in epinephrine delivery as the first and only needle-free treatment […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: aptarpharma, arspharmaceuticals

Aptar wins FDA contract to study low global warning potential metered dose inhalers

December 4, 2023 By Sean Whooley

Aptar Pharma inhaler

Aptar Pharma announced today that it entered into a contract with the FDA to work on low global warming potential (low-GWP) inhalers. The FDA enlisted Aptar to study the challenges of developing low-GWP propellant metered dose inhalers (MDIs). The Crystal Lake, Illinois-based company expects its study to help define the potential target product profile of […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Funding Roundup Tagged With: aptarpharma, FDA

Aptar Pharma launches metal-free nasal spray pump

January 30, 2023 By Sean Whooley

Aptar Pharma APF Futurity metal-free nasal spray pump

Aptar Pharma announced today that it launched its first metal-free, multidose nasal spray pump, called the APF Futurity. Crystal Lake, Illinois-based Aptar developed APF Futurity to deliver nasal saline and other comparable over-the-counter (OTC) formulations. The company designed the pump specifically for recyclability. It represents Aptar’s first “highly recyclable” nasal spray pump, according to a […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: aptarpharma

Aptar acquires Orbital dry powder inhaler license

August 4, 2022 By Sean Whooley

Aptar Pharmaxis Orbital dry powder inhaler

Aptar Pharma announced today that it acquired the worldwide writes to Pharmaxis’ proprietary Orbital inhaler. Pharmaxis designed its Orbital technology to deliver high-payload dry powder to the lungs, helping to meet the need to deliver high doses of drugs such as antibiotics. According to a news release, the Orbital inhaler allows payloads of up to […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Respiratory Tagged With: aptarpharma

FDA approves first nasally administered pharmaceutical treatment for dry eye

October 25, 2021 By Sean Whooley

Aptar Pharma Oyster Point CPS Tyrvaya

AptarGroup (NYSE:ATR) announced today that it received FDA approval for its nasal pump to deliver a pharmaceutical treatment for dry eye. Crystal Lake, Illinois–based Aptar said the patented Cartridge Pump System (CPS) is for the multidose delivery of preserved and non-preserved drug formulations. It has received approval as the device for delivering Oyster Point Pharma’s […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance Tagged With: aptarpharma, FDA, oysterpointpharma

Seelos, Aptar sign deal for Bidose system to deliver ketamine candidate

April 6, 2021 By Sean Whooley

Seelos Therapeutics AptarGroup Aptar Pharma

Seelos Therapeutics (NSDQ:SEEL) announced today that it partnered with AptarGroup (NYSE:ATR) for the Bidose liquid system device. The agreement includes the co-exclusive use and supply of Aptar Pharma’s Bidose device to deliver Seelos’ intranasal ketamine product candidate, SLS-002, for treating suicidality, depression and post-traumatic stress disorder (PTSD). Under the agreement, Seelos garners certain rights to […]

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Neurological Tagged With: aptarpharma, Seelos Therapeutics

Aptar wins FDA clearance for ready-to-use seizure treatment device

December 9, 2019 By Danielle Kirsh

aptar-logo

AptarGroup today said it won FDA approval for its Unidose Liquid System that treats acute repetitive seizures in people who have epilepsy. The Unidose Liquid System is a device that delivers a nasal rescue treatment that is ready-to-use when and where a seizure cluster occurs. “This approval and successful market launch further demonstrate the broad […]

Filed Under: Drug-Device Combinations, Pharmaceuticals Tagged With: aptarpharma, epilepsy

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS